Inhibitory effects of octreotide on renal and glomerular growth in early experimental diabetes in mice

Journal of Endocrinology

Volumn 172, Issue 3, 2002, Pages 637-643

  Gronbaek H ^a   Nielsen, B ^a   Schrijvers, B ^a   Vogel, I ^a   Rasch, R ^a   Flyvbjerg, A ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; OCTREOTIDE; PLACEBO; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETES CONTROL; DIABETOGENESIS; DRUG EFFECT; DRUG FORMULATION; FEMALE; FOOD INTAKE; GLOMERULUS; GROWTH INHIBITION; HORMONE RELEASE; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DEVELOPMENT; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZATION; STREPTOZOCIN DIABETES; TISSUE DISTRIBUTION;

ANALYSIS OF VARIANCE; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; FEMALE; GROWTH HORMONE; HORMONES; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; KIDNEY; KIDNEY GLOMERULUS; MICE; MICE, INBRED BALB C; OCTREOTIDE; RANDOM ALLOCATION; SOMATOSTATIN;

EID: 18344372576     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.0.1720637     Document Type: Article

References (38)

1. Effects of streptozotocin treatment in growth hormone (GH) and GH antagonist transgenic mice
2. A growth hormone antagonist protects mice against streptozotocin induced glomerulosclerosis even in the presence of elevated levels of glucose and glycated hemoglobin
3. Modulation of insulin like growth factor I binding to human fibroblast monolayer cultures by insulin like growth factor carrier proteins released to the incubation media
4. Progressive glomerulosclerosis develops in transgenic mice chronically expressing growth hormone and growth hormone releasing factor but not in those expressing insulin like growth factor-1
5. Glomerular lesions in mice transgenic for growth hormone and insulin like growth factor-I. I. Relationship between increased glomerular size and mesangial sclerosis
6. Inhibition of diabetic nephropathy by a GH antagonist: A molecular analysis
7. Growth factors and diabetic complications
8. Role of growth hormone, insulin-like growth factors (IGFs) and IGF-binding proteins in the renal complications of diabetes
9. Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease
10. Somatostatin analogue administration prevents increase in kidney somatomedin C and initial renal growth in diabetic and uninephrectomized rats
11. Octreotide administration in diabetic rats: Effects on renal hypertrophy and urinary albumin excretion
12. Kidney IGF-I and renal hypertrophy in GH-deficient diabetic dwarf rats
13. Transient increase in renal insulin-like growth factor binding proteins during initial kidney hypertrophy in experimental diabetes in rats
14. The role of growth factors in renal complications of diabetes
15. Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy, and urinary albumin excretion in experimental diabetes in mice
16. Potential role of octreotide in the treatment of diabetes
17. The effect of angiopeptin, a somatostatin analogue, on circulating IGFBP and initial renal hypertrophy in experimental diabetes in rats
18. Effect of octreotide and insulin on manifest renal and glomerular hypertrophy and urinary albumin excretion in long-term experimental diabetes in rats
19. Effect of octreotide on experimental diabetic renal and glomerular growth: Importance of early intervention
20. Effect of lanreotide on local kidney IGF-I changes and renal growth in experimental diabetes in the rat
21. Effect of GH/IGF-I deficiency on long-term renal changes and urinary albumin excretion in diabetic dwarf rats
22. Effect of octreotide, captopril or insulin on renal changes and UAE in long-term experimental diabetes
23. Growth hormone, insulin-like growth factors, and somatostatin analogues in clinical and experimental diabetes
24. The nucleator
25. Serum growth hormone patterns in juvenile diabetes
26. Diurnal pattern of blood glucose, serum FFA, insulin, glucagon, and growth hormone in normals and juvenile diabetics
27. Analysis of serum insulin-like growth factor binding proteins using Western blotting: Use of the method for titration of the binding proteins and competitive binding studies
28. Expression of insulin-like growth factor binding proteins in the rat kidney: Effects of long-term diabetes
29. Differential expression of renal growth hormone receptor and its binding protein in experimental diabetes mellitus
30. Changes in the growth hormone-IGF-I axis in non-obese diabetic mice
31. A novel somatostatin analogue prevents early renal complications in the nonobese diabetic mouse
32. Octreotide prevents the early increase in renal insulin-like growth factor binding protein 1 in streptozotocin diabetic rats
33. Insulin-like growth factor (IGF) binding protein from human decidua inhibits the binding and biological action of IGF-I in cultured choriocarcinoma cells
34. Insulin, IGF-I and growth in diabetic rats
35. Renal hypertrophy in hyperglycemic non-obese diabetic mice is associated with persistent renal accumulation of insulin-like growth factor I
36. Regulation of immunoreactive growth hormone secretion in male rats
37. Growth hormone secretion dynamics in streptozotocin diabetes: Evidence of a role for endogenous somatostatin
38. Abnormal growth hormone response to ingestion of glucose in juvenile diabetics